GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

All doses of Eli Lilly & Co.’s blockbuster new drugs to treat diabetes and weight loss are available in the US after more than a year and a half of shortages. The Food and Drug Administration ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Last week, Australia ’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

It was only a matter of time until the GLP-1 receptor agonist drugs like ... and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on ...

America's famous drug manufacturer Eli Lilly has launched the weight loss ... Now its availability in India is expected to provide great relief to patients suffering from obesity and type-2 diabetes.